This 0.5-hour, Whiteboard Animation Webcast is designed to review clinical trial and deal-world data for DOAC and other anticoagulation therapeutics for VTE. A majority of new diagnoses of VTE are made by primary care professionals. Evidence-based guidelines for the management of VTE include the most recent updates from the American Society of Hematology (ASH, 2020), the European Society of Cardiology (ESC, 2019), and the American College of Chest Physicians (ACCP/CHEST, 2021). These guidelines recommend using DOACs as the first choice for anticoagulation in eligible VTE patients, and also give preference under risk-directed assessment to outpatient treatment. The use of DOAC monotherapy is implicitly straightforward and streamlined for continuity of care.
Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE
Analyze contemporary clinical trial and observational data for DOAC and other anticoagulation therapeutics for VTE
Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Geoffrey Barnes, MD, MSc | Consultant/Advisor: Abbott Vascular; Boston Scientific; Bristol-Myers Squib; Janssen; Pfizer
Board of Directors: Anticoagulation Forum |
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-24-002-H01-P.)
Learners should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from the Bristol Myers Squibb and Pfizer Alliance.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Bristol Myers Squibb and Pfizer Alliance do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
